Navigation Links
India's Favorable and Progressive Regulatory Environment Causes Accelerated Growth of Max Neeman International's Regulatory Services
Date:10/11/2010

RESEARCH TRIANGLE PARK, N.C., Oct. 11 /PRNewswire/ -- India has evolved into a preferred destination for conducting clinical trials in large part because the Indian Regulatory bodies have created an environment which is focused on quality, transparency and protection in research activities.  Regulatory standards meet the requirements of ICH GCP, ICMR (Indian Council of Medical Research) and all the other regulatory bodies across the globe.

Owing to the favorable regulatory environment in India, Max Neeman's regulatory services have grown tremendously over the past few years and team members are qualified with more than 5 years of regulatory experience.  They specialize in providing the most effective regulatory assessment and strategy for timely submission and early approval. A systematic approach, rigorous follow-up and dedicated resources provide regulatory solutions for successful completion of the drug development cycle for clients.

The main regulatory body of India's government overseeing clinical trial research is the Drug Controller of India, Ministry of Health and Family Welfare, Government of India (DCGI).  DCGI is similar to the United States FDA who opened only the second non-USA office in India in 2009.  The Max Neeman team is updated with the all the recent and upcoming regulatory reforms initiated by the regulatory bodies in India and has the relationships to liaise with them effectively.

Based on each client's requirements, the regulatory team helps in developing:

  • regulatory strategy per client's requirements
  • regulatory submission and approval for initiating the trial
  • a review and evaluation of the pre-clinical data to provide step wise assistance in responding to questions by a regulatory body

Max Neeman will continue to maintain a strong regulatory team in support of India's progressive regulatory environment and the client's needs.

About Max Neeman International

Max Neeman International is a leading India-based CRO. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 31 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
2. Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
3. Hospira Receives Favorable Court Decision on Eloxatin(R)
4. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
5. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
6. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
7. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
8. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
9. OXPEKK-IG Device Viking Gains Regulatory Approval in Korea
10. Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America
11. Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The ... three Winners and six Finalists of the 2017 Blavatnik Regional Awards for Young ... Family Foundation and administered by the New York Academy of Sciences to honor ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first-ever genomics analysis platform specifically designed for life science researchers to analyze ... pioneering researcher Rosalind Franklin, who made a major contribution to the discovery ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
(Date:5/23/2017)... May 23, 2017  Hunova, the first robotic gym for the rehabilitation ... officially launched in Genoa, Italy . The first 30 ... and the USA . The technology was developed and ... by the IIT spin-off Movendo Technology thanks to a 10 million euro ... Release, please click: ...
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
Breaking Biology News(10 mins):